Publications - 2015


email this

Publications -2015

  1. Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies
    Wilton B. Williams, Hua-Xin Liao, M. Anthony Moody, Thomas B. Kepler, S. Munir Alam, Feng Gao, Kevin Wiehe, Ashley M. Trama, Kathryn Jones, Ruijun Zhang, Hongshuo Song, Dawn J. Marshall, John F. Whitesides, Kaitlin Sawatzki, Axin Hua, Pinghuang Liu, Matthew Z. Tay, Kelly Seaton, Xiaoying Shen, Andrew Foulger, Krissey E. Lloyd, Robert Parks, Justin Pollara, Guido Ferrari, Jae-Sung Yu, Nathan Vandergrift, David C. Montefiori, Magdalena E. Sobieszczyk, Scott Hammer, Shelly Karuna, Peter Gilbert, Doug Grove, Nicole Grunenberg, Julie McElrath, John R. Mascola, Richard A. Koup, Lawrence Corey, Gary J. Nabel, Cecilia Morgan, Gavin Churchyard, Janine Maenza, Michael Keefer, Barney S. Graham, Lindsey R. Baden, Georgia D. Tomaras, and Barton F. Haynes Science aab1253Published online 30 July 2015 [DOI:10.1126/science.aab1253]
  2. Maternal HIV-1 envelope-specific antibody responses and reduced risk of perinatal transmission.
    Permar SR, Fong Y, Vandergrift N, Fouda GG, Gilbert P, Parks R, Jaeger FH, Pollara J, Martelli A, Liebl BE, Lloyd K, Yates NL, Overman RG, Shen X, Whitaker K, Chen H, Pritchett J, Solomon E, Friberg E, Marshall DJ, Whitesides JF, Gurley TC, Von Holle T, Martinez DR, Cai F, Kumar A, Xia SM, Lu X, Louzao R, Wilkes S, Datta S, Sarzotti-Kelsoe M, Liao HX, Ferrari G, Alam SM, Montefiori DC, Denny TN, Moody MA, Tomaras GD, Gao F, Haynes BF. J Clin Invest. 2015 Jun 8. pii: 81593. doi: 10.1172/JCI81593.
  3. New approaches to HIV vaccine development.
    Haynes BF. Curr Opin Immunol. 2015 Jun 4;35:39-47. doi: 10.1016/j.coi.2015.05.007. Review. PMID: 26056742
  4. A new model for catalyzing translational science: the early stage investigator mentored research scholar program in HIV vaccines.
    Adamson BJ, Fuchs JD, Sopher CJ, Flood DM, Johnson RP, Haynes BF, Kublin JG; NIAID HIV Vaccine Trials Network. Clin Transl Sci. 2015 Apr;8(2):166-8.
  5. Designing synthetic vaccines for HIV.
    Fernández-Tejada A, Haynes BF, Danishefsky SJ. Expert Rev Vaccines. 2015 Jun;14(6):815-31.
  6. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
    Sung JA, Pickeral J, Liu L, Stanfield-Oakley SA, Lam CY, Garrido C, Pollara J, LaBranche C, Bonsignori M, Moody MA, Yang Y, Parks R, Archin N, Allard B, Kirchherr J, Kuruc JD, Gay CL, Cohen MS, Ochsenbauer C, Soderberg K, Liao HX, Montefiori D, Moore P, Johnson S, Koenig S, Haynes BF, Nordstrom JL, Margolis DM, Ferrari G. J Clin Invest. 2015 Nov 2;125(11):4077-90.
  7. Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes.
    Asmal M, Luedemann C, Lavine CL, Mach LV, Balachandran H, Brinkley C, Denny TN, Lewis MG, Anderson H, Pal R, Sok D, Le K, Pauthner M, Hahn BH, Shaw GM, Seaman MS, Letvin NL, Burton DR, Sodroski JG, Haynes BF, Santra S. Virology. 2015 Jan 15;475:37-45. 
  8. Virological features associated with the development of broadly neutralizing antibodies to HIV-1.
    Moore PL, Williamson C, Morris L. Trends Microbiol. 2015 Apr;23(4):204-11.
  9. Improving neutralization potency and breadth by combining broadly reactive HIV-1 antibodies targeting major neutralization epitopes.
    Kong R, Louder MK, Wagh K, Bailer RT, deCamp A, Greene K, Gao H, Taft JD, Gazumyan A, Liu C, Nussenzweig MC, Korber B, Montefiori DC, Mascola JR. J Virol. 2015 Mar;89(5):2659-71. 
  10. Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage.
    Xu H, Schmidt AG, O'Donnell T, Therkelsen MD, Kepler TB, Moody MA, Haynes BF, Liao HX, Harrison SC, Shaw DE. Proteins. 2015 Apr;83(4):771-80.
  11. Polyreactivity and autoreactivity among HIV-1 antibodies.
    Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J, Haynes BF, Kelsoe G. J Virol. 2015 Jan;89(1):784-98. 
  12. Infant HIV type 1 gp120 vaccination elicits robust and durable anti-V1V2 immunoglobulin G responses and only rare envelope-specific immunoglobulin A responses.
    Fouda GG, Cunningham CK, McFarland EJ, Borkowsky W, Muresan P, Pollara J, Song LY, Liebl BE, Whitaker K, Shen X, Vandergrift NA, Overman RG, Yates NL, Moody MA, Fry C, Kim JH, Michael NL, Robb M, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Liao HX, Haynes BF, Montefiori DC, Ferrari G, Tomaras GD, Permar SR. J Infect Dis. 2015 Feb 15;211(4):508-17.
  13. Transmitted virus fitness and host T cell responses collectively define divergent infection outcomes in two HIV-1 recipients.
    Yue L, Pfafferott KJ, Baalwa J, Conrod K, Dong CC, Chui C, Rong R, Claiborne DT, Prince JL, Tang J, Ribeiro RM, Cormier E, Hahn BH, Perelson AS, Shaw GM, Karita E, Gilmour J, Goepfert P, Derdeyn CA, Allen SA, Borrow P, Hunter E. PLoS Pathog. 2015 Jan 8;11(1):e1004565. 
  14. Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women.
    Sacha CR, Vandergrift N, Jeffries TL Jr, McGuire E, Fouda GG, Liebl B, Marshall DJ, Gurley TC, Stiegel L, Whitesides JF, Friedman J, Badiabo A, Foulger A, Yates NL, Tomaras GD, Kepler TB, Liao HX, Haynes BF, Moody MA, Permar SR. Mucosal Immunol. 2015 Mar;8(2):316-26. 
  15. Eliminating antibody polyreactivity through addition of N-linked glycosylation.
    Chuang GY, Zhang B, McKee K, O'Dell S, Kwon YD, Zhou T, Blinn J, Lloyd K, Parks R, Von Holle T, Ko SY, Kong WP, Pegu A, Wang K, Baruah K, Crispin M, Mascola JR, Moody MA, Haynes BF, Georgiev IS, Kwong PD. Protein Sci. 2015 Jun;24(6):1019-30. 
  16. Post-treatment control of HIV infection.
    Conway JM, Perelson AS. Proc Natl Acad Sci U S A. 2015 Apr 28;112(17):5467-72. 
  17. Stable Expression of Lentiviral Antigens by Quality-Controlled Recombinant Mycobacterium bovis BCG Vectors.
    Hart BE, Asrican R, Lim SY, Sixsmith JD, Lukose R, Souther SJ, Rayasam SD, Saelens JW, Chen CJ, Seay SA, Berney-Meyer L, Magtanong L, Vermeul K, Pajanirassa P, Jimenez AE, Ng TW, Tobin DM, Porcelli SA, Larsen MH, Schmitz JE, Haynes BF, Jacobs WR Jr, Lee S, Frothingham R. Clin Vaccine Immunol. 2015 Jul;22(7):726-41. 
  18. Inhibitory Effect of Individual or Combinations of Broadly Neutralizing Antibodies and Antiviral Reagents against Cell-Free and Cell-to-Cell HIV-1 Transmission.
    Gombos RB, Kolodkin-Gal D, Eslamizar L, Owuor JO, Mazzola E, Gonzalez AM, Korioth-Schmitz B, Gelman RS, Montefiori DC, Haynes BF, Schmitz JE. J Virol. 2015 Aug;89(15):7813-28. 
  19. Rhesus immune responses to SIV Gag expressed by recombinant BCG vectors are independent from pre-existing mycobacterial immunity.
    Korioth-Schmitz B, Perley CC, Sixsmith JD, Click EM, Lee S, Letvin NL, Frothingham R. Vaccine. 2015 Oct 13;33(42):5715-22. 
  20. Strain-Specific V3 and CD4 Binding Site Autologous HIV-1 Neutralizing Antibodies Select Neutralization-Resistant Viruses.
    Moody MA, Gao F, Gurley TC, Amos JD, Kumar A, Hora B, Marshall DJ, Whitesides JF, Xia SM, Parks R, Lloyd KE, Hwang KK, Lu X, Bonsignori M, Finzi A, Vandergrift NA, Alam SM, Ferrari G, Shen X, Tomaras GD, Kamanga G, Cohen MS, Sam NE, Kapiga S, Gray ES, Tumba NL, Morris L, Zolla-Pazner S, Gorny MK, Mascola JR, Hahn BH, Shaw GM, Sodroski JG, Liao HX, Montefiori DC, Hraber PT, Korber BT, Haynes BF. Cell Host Microbe. 2015 Sep 9;18(3):354-62. 
  21. Identification of effective subdominant anti-HIV-1 CD8+ T cells within entire post-infection and post-vaccination immune responses.
    Hancock G, Yang H, Yorke E, Wainwright E, Bourne V, Frisbee A, Payne TL, Berrong M, Ferrari G, Chopera D, Hanke T, Mothe B, Brander C, McElrath MJ, McMichael A, Goonetilleke N, Tomaras GD, Frahm N, Dorrell L. PLoS Pathog. 2015 Feb 27;11(2):e1004658. 
  22. Exploring the feasibility of multi-site flow cytometric processing of gut associated lymphoid tissue with centralized data analysis for multi-site clinical trials.
    McGowan I, Anton PA, Elliott J, Cranston RD, Duffill K, Althouse AD, Hawkins KL, De Rosa SC. PLoS One. 2015 May 26;10(5):e0126454. 
  23. Vaccine-Induced Linear Epitope-Specific Antibodies to Simian Immunodeficiency Virus SIVmac239 Envelope Are Distinct from Those Induced to the Human Immunodeficiency Virus Type 1 Envelope in Nonhuman Primates.
    Shen X, Duffy R, Howington R, Cope A, Sadagopal S, Park H, Pal R, Kwa S, Ding S, Yang OO, Fouda GG, Le Grand R, Bolton D, Esteban M, Phogat S, Roederer M, Amara RR, Picker LJ, Seder RA, McElrath MJ, Barnett S, Permar SR, Shattock R, DeVico AL, Felber BK, Pavlakis GN, Pantaleo G, Korber BT, Montefiori DC, Tomaras GD. J Virol. 2015 Aug;89(16):8643-50. 

Publications -2014

  1. Kernel-based logistic regression model for protein sequence without vectorialization.
    Fong Y, Datta S, Georgiev IS, Kwong PD, Tomaras GD. Biostatistics. 2014 Dec 22. pii: kxu056.

  2. Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved.
    Wiehe K, Easterhoff D, Luo K, Nicely NI, Bradley T, Jaeger FH, Dennison SM, Zhang R, Lloyd KE, Stolarchuk C, Parks R, Sutherland LL, Scearce RM, Morris L, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Sinangil F, Phogat S, Michael NL, Kim JH, Kelsoe G, Montefiori DC, Tomaras GD, Bonsignori M, Santra S, Kepler TB, Alam SM, Moody MA, Liao HX, Haynes BF. Immunity. 2014 Dec 18;41(6):909-18.

  3. Key mutations stabilize antigen-binding conformation during affinity maturation of a broadly neutralizing influenza antibody lineage.
    Xu H, Schmidt AG, O'donnell T, Therkelsen MD, Kepler TB, Moody MA, Haynes BF, Liao H, Harrison SC, Shaw DE. Proteins. 2014 Dec 18.

  4. Innate Activation of MDC and NK Cells in High-risk HIV-1 Exposed, Sero-Negative (HESN) IV-Drug Users that Share Needles When Compared to Low-risk Non-sharing IV-Drug User Controls.
    Tomescu C, Seaton KE, Smith P, Taylor M, Tomaras GD, Metzger DS, Montaner LJ. J Acquir Immune Defic Syndr. 2014 Dec 13.

  5. Lifespan-extending caloric restriction or mTOR inhibition impair adaptive immunity of old mice by distinct mechanisms.
    Goldberg EL, Romero-Aleshire MJ, Renkema KR, Ventevogel MS, Chew WM, Uhrlaub JL, Smithey MJ, Limesand KH, Sempowski GD, Brooks HL, Nikolich-Žugich J. Aging Cell. 2014 Nov 26.

  6. Infection of monkeys by simian-human immunodeficiency viruses with transmitted/founder clade C HIV-1 envelopes.
    Asmal M, Luedemann C, Lavine CL, Mach LV, Balachandran H, Brinkley C, Denny TN, Lewis MG, Anderson H, Pal R, Sok D, Le K, Pauthner M, Hahn BH, Shaw GM, Seaman MS, Letvin NL, Burton DR, Sodroski JG, Haynes BF, Santra S. Virology. 2014 Nov 22;475C:37-45.

  7. Impact of clade, geography, and age of the epidemic on HIV-1 neutralization by antibodies.
    Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, Greene KM, McCutchan F, Williamson C, Kim JH, Tovanabutra S, Hahn BH, Swanstrom R, Thomson MM, Gao F, Harris L, Giorgi E, Hengartner N, Bhattacharya T, Mascola JR, Montefiori DC. J Virol. 2014 Nov;88(21):12623-43.

  8. Preexisting compensatory amino acids compromise fitness costs of a HIV-1 T cell escape mutation.
    Liu D, Zuo T, Hora B, Song H, Kong W, Yu X, Goonetilleke N, Bhattacharya T, Perelson AS, Haynes BF, McMichael AJ, Gao F. Retrovirology. 2014 Nov 19;11(1):101.

  9. Induction of Antibodies with Long Variable Heavy Third Complementarity Determining Regions by Repetitive Boosting with AIDSVAX® B/E in RV144 Vaccinees.
    Moody MA, Easterhoff D, Gurley TC, Whitesides JF, Marshall DJ, Foulger A, Lloyd KE, Parks R, Pollara J, Duffy R, Shen S, Kim JH, Michael NL, Robb ML, O'Connell RJ, Vasan S, Excler JL, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Nitayaphan S, Sinangil F, Francis D, Lee C, Kepler TB, Alam SM, Ferrari G, Montefiori DC, Liao HX, Tomaras GD, Haynes BF. AIDS Res Hum Retroviruses. 2014 Oct; 30(S1): A36. No abstract available.

  10. Role of Intestinal Microbiota in Shaping the B Cell Repertoire in HIV Infection and Env Vaccination.
    Liao LH, Trama AM, Williams WB, Moody MA, Vandergrift N, Tomaras GD, Marshall DJ, Gurley T, Whitesides J, Eudailey J, Foulger A, Parks R, Stolarchuk C, Lloyd KE, Soderberg K, Mascola JR, Koup R, Corey L, Nabel GB, Gilber P, Morgan C, Maenza J, Keefer M, Hammer S, Churchyard G, Montefior DC, Graham BS, Baden LR, Kepler TB, Haynes BF. AIDS Res Hum Retroviruses. 2014 Oct; 30(S1): A19. No abstract available.

  11. Polyreactivity and Autoreactivity among HIV-1 Antibodies.
    Liu M, Yang G, Wiehe K, Nicely NI, Vandergrift NA, Rountree W, Bonsignori M, Alam SM, Gao J,Haynes BF, Kelsoe G. J Virol. 2014 Oct 29. pii: JVI.02378-14.

  12. Structure and immune recognition of trimeric pre-fusion HIV-1 Env.
    Pancera M, Zhou T, Druz A, Georgiev IS, Soto C, Gorman J, Huang J, Acharya P, Chuang GY, Ofek G, Stewart-Jones GB, Stuckey J, Bailer RT, Joyce MG, Louder MK, Tumba N, Yang Y, Zhang B, Cohen MS, Haynes BF, Mascola JR, Morris L, Munro JB, Blanchard SC, Mothes W, Connors M, Kwong PD. Nature. 2014 Oct 8. doi: 10.1038/nature13808.

  13. Gene Deletions in BCG Stimulate Increased CD8+ T Cell Responses.
    Panas MW, Sixsmith JD, White K, Korioth-Schmitz B, Shields ST, Moy BT, Lee S, Schmitz JE, Jacobs WR Jr, Porcelli SA, Haynes BF, Letvin NL, Gillard GO. Infect Immun. 2014 Oct 6. pii: IAI.02100-14.

  14. Aggregate complexes of HIV-1 induced by multimeric antibodies.
    Stieh DJ, King DF, Klein K, Liu P, Shen X, Hwang K, Ferrari G, Montefiori DC, Haynes B, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Rerks-Ngarm S, Michael NL, Robb ML, Kim JH, Denny TN, Tomaras GD, Shattock RJ. Retrovirology. 2014 Oct 2;11(1):78.

  15. HIV-specific humoral responses benefit from stronger prime in phase Ib clinical trial.
    Bart PA, Huang Y, Karuna ST, Chappuis S, Gaillard J, Kochar N, Shen X, Allen MA, Ding S, Hural J, Liao HX, Haynes BF, Graham BS, Gilbert PB, McElrath MJ, Montefiori DC, Tomaras GD, Pantaleo G, Frahm N. J Clin Invest. 2014 Oct 1. pii: 75894. doi: 10.1172/JCI75894.

  16. Improving Mycobacterium bovis Bacillus Calmette-Guèrin as a Vaccine Delivery Vector for Viral Antigens by Incorporation of Glycolipid Activators of NKT Cells.
    Venkataswamy MM, Ng TW, Kharkwal SS, Carreño LJ, Johnson AJ, Kunnath-Velayudhan S, Liu Z, Bittman R, Jervis PJ, Cox LR, Besra GS, Wen X, Yuan W, Tsuji M, Li X, Ho DD, Chan J, Lee S, Frothingham R, Haynes BF, Panas MW, Gillard GO, Sixsmith JD, Korioth-Schmitz B, Schmitz JE, Larsen MH, Jacobs WR Jr, Porcelli SA. PLoS One. 2014 Sep 25;9(9):e108383. doi: 10.1371/journal.pone.0108383. eCollection 2014.

  17. Tolerance and immunity after sequential lung and bone marrow transplantation from an unrelated cadaveric donor.
    Szabolcs P, Buckley RH, Davis RD, Moffet J, Voynow J, Antony J, Chen X, Sempowski GD, Zaas DW. J Allergy Clin Immunol. 2014 Sep 24. pii: S0091-6749(14)01112-9. doi: 10.1016/j.jaci.2014.07.058. [Epub ahead of print] No abstract available.

  18. TLR2 Signaling is Required for the Innate, but Not Adaptive Response to LVS clpB.
    Roberts LM, Ledvina HE, Sempowski GD, Frelinger JA. Front Immunol. 2014 Sep 5;5:426. doi: 10.3389/fimmu.2014.00426. eCollection 2014.

  19. Extensive Recombination Due to Heteroduplexes Generates Large Amounts of Artificial Gene Fragments during PCR.
    Liu J, Song H, Liu D, Zuo T, Lu F, Zhuang H, Gao F. PLoS One. 2014 Sep 11;9(9):e106658. doi: 10.1371/journal.pone.0106658. eCollection 2014.

  20. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses.
    Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, Bernard N, Tremblay C, Roger M, Kaufmann DE, Finzi A. J Virol Methods. 2014 Aug 12;208C:107-114. doi: 10.1016/j.jviromet.2014.08.003.

  21. Immunoglobulin Gene Insertions and Deletions in the Affinity Maturation of HIV-1 Broadly Reactive Neutralizing Antibodies.
    Kepler TB, Liao HX, Alam SM, Bhaskarabhatla R, Zhang R, Yandava C, Stewart S, Anasti K, Kelsoe G, Parks R, Lloyd KE, Stolarchuk C, Pritchett J, Solomon E, Friberg E, Morris L, Karim SS, Cohen MS, Walter E, Moody MA, Wu X, Altae-Tran HR, Georgiev IS, Kwong PD, Boyd SD, Fire AZ, Mascola JR,Haynes BF. Cell Host Microbe. 2014 Sep 10;16(3):304-313. doi: 10.1016/j.chom.2014.08.006.

  22. Broad and potent HIV-1 neutralization by a human antibody that binds the gp41-gp120 interface.
    Huang J, Kang BH, Pancera M, Lee JH, Tong T, Feng Y, Georgiev IS, Chuang GY, Druz A, Doria-Rose NA, Laub L, Sliepen K, van Gils MJ, de la Peña AT, Derking R, Klasse PJ, Migueles SA, Bailer RT, Alam M, Pugach P, Haynes BF, Wyatt RT, Sanders RW, Binley JM, Ward AB, Mascola JR, Kwong PD, Connors M. Nature. 2014 Sep 3. doi: 10.1038/nature13601.

  23. Potent immune responses in rhesus macaques induced by non-viral delivery of a self-amplifying RNA vaccine expressing HIV-1 envelope with a cationic nanoemulsion.
    Bogers WM, Oostermeijer H, Mooij P, Koopman G, Verschoor EJ, Davis D, Ulmer JB, Brito LA, Cu Y, Banerjee K, Otten GR, Burke B, Dey A, Heeney JL, Shen X, Tomaras GD, Labranche C, Montefiori DC, Liao HX, Haynes B, Geall AJ, Barnett SW. J Infect Dis. 2014 Sep 18. pii: jiu522.

  24. Editor's Choice: Infant HIV-1 gp120 vaccination elicits robust and durable anti-V1V2 IgG responses and only rare Envelope-specific IgA responses.
    Genevieve G. Fouda, Coleen K. Cunningham, Elizabeth J. McFarland, William Borkowsky, Petronella Muresan, Justin Pollara, Lin Ye Song, Brooke E. Liebl, Kaylan Whitaker, Xiaoying Shen, Nathan A. Vandergrift, R. Glenn Overman, Nicole L. Yates, M. Anthony Moody, Carrie Fry, Jerome H. Kim, Nelson L. Michael, Merlin Robb, Punnee Pitisuttithum, Jaranit Kaewkungwal, Sorachai Nitayaphan, Supachai Rerks-Ngarm, Hua-Xin Liao, Barton F. Haynes, David C. Montefiori, Guido Ferrari, Georgia D. Tomaras, and Sallie R. Permar. J Infect Dis. First published online August 27, 2014 doi:10.1093/infdis/jiu444

  25. Enhanced potency of a broadly neutralizing HIV-1 antibody in vitro improves protection against lentiviral infection in vivo.
    Rudicell RS, Kwon YD, Ko SY, Pegu A, Louder MK, Georgiev IS, Wu X, Zhu J, Boyington JC, Chen X, Shi W, Yang ZY, Doria-Rose NA, McKee K, O'Dell S, Schmidt SD, Chuang GY, Druz A, Soto C, Yang Y, Zhang B, Zhou T, Todd JP, Lloyd KE, Eudailey J, Roberts KE, Donald BR, Bailer RT, Ledgerwood J; NISC Comparative Sequencing Program, Mullikin JC, Shapiro L, Koup RA, Graham BS, Nason MC, Connors M, Haynes BF, Rao SS, Roederer M, Kwong PD, Mascola JR, Nabel GJ. J Virol. 2014 Aug 20. pii: JVI.02213-14.

    Hraber P, Korber BT, Lapedes AS, Bailer RT, Seaman MS, Gao H, Greene KM, McCutchan F, Williamson C, Kim JH, Tovanabutra S, Hahn BH, Swanstrom R, Thomson MM, Gao F, Harris L, Giorgi E, Hengartner N, Bhattacharya T, Mascola JR, Montefiori DC. J Virol. 2014 Aug 20. pii: JVI.01705-14.

  27. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses.
    Richard J, Veillette M, Batraville LA, Coutu M, Chapleau JP, Bonsignori M, Bernard N, Tremblay C, Roger M, Kaufmann DE, Finzi A. J Virol Methods. 2014 Aug 12. pii: S0166-0934(14)00310-3. doi: 10.1016/j.jviromet.2014.08.003.

  28. HIV-1 Envelope gp41 Antibodies Can Originate from Terminal Ileum B Cells that Share Cross-Reactivity with Commensal Bacteria.
    Trama AM, Moody MA, Alam SM, Jaeger FH, Lockwood B, Parks R, Lloyd KE, Stolarchuk C, Scearce R, Foulger A, Marshall DJ, Whitesides JF, Jeffries TL Jr, Wiehe K, Morris L, Lambson B, Soderberg K, Hwang KK, Tomaras GD, Vandergrift N, Jackson KJ, Roskin KM, Boyd SD, Kepler TB, Liao HX,Haynes BF. Cell Host Microbe. 2014 Aug 13;16(2):215-226. doi: 10.1016/j.chom.2014.07.003.

  29. Progress in HIV-1 vaccine development.
    Haynes BF, Moody MA, Alam M, Bonsignori M, Verkoczy L, Ferrari G, Gao F, Tomaras GD, Liao HX, Kelsoe G. J Allergy Clin Immunol. 2014 Jul;134(1):3-10. doi: 10.1016/j.jaci.2014.04.025. Epub 2014 Jun 26. Review.

  30. FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.
    Li SS, Gilbert PB, Tomaras GD, Kijak G, Ferrari G, Thomas R, Pyo CW, Zolla-Pazner S, Montefiori D, Liao HX, Nabel G, Pinter A, Evans DT, Gottardo R, Dai JY, Janes H, Morris D, Fong Y, Edlefsen PT, Li F, Frahm N, Alpert MD, Prentice H, Rerks-Ngarm S, Pitisuttithum P, Kaewkungwal J, Nitayaphan S, Robb ML, O'Connell RJ, Haynes BF, Michael NL, Kim JH, McElrath MJ, Geraghty DE. J Clin Invest. 2014 Aug 8. pii: 75539. doi: 10.1172/JCI75539.

  31. Restricted isotype, distinct variable gene usage, and high rate of gp120 specificity of HIV-1 envelope-specific B cells in colostrum compared with those in blood of HIV-1-infected, lactating African women.
    Sacha CR, Vandergrift N, Jeffries TL Jr, McGuire E, Fouda GG, Liebl B, Marshall DJ, Gurley TC, Stiegel L, Whitesides JF, Friedman J, Badiabo A, Foulger A, Yates NL, Tomaras GD, Kepler TB, Liao HX, Haynes BF, Moody MA, Permar SR.
    Mucosal Immunol. 2014 Aug 6. doi: 10.1038/mi.2014.69.

  32. Recombinant Bacillus Calmette-Guérin vectors prime for strong cellular responses to SIV Gag in rhesus macaques.
    Sixsmith JD, Panas MW, Lee S, Gillard GO, White K, Lifton MA, Balachandran H, Mach L, Miller JP, Lavine C, DeMarco CT, Tomaras GD, Gee C, Porcelli SA, Larsen MH, Frothingham R, Schmitz JE, Jacobs WR Jr, Haynes BF, Letvin NL, Korioth-Schmitz B. Clin Vaccine Immunol. 2014 Jul 30. pii: CVI.00324-14.

  33. Cooperation of B Cell Lineages in Induction of HIV-1-Broadly Neutralizing Antibodies.
    Gao F, Bonsignori M, Liao HX, Kumar A, Xia SM, Lu X, Cai F, Hwang KK, Song H, Zhou T, Lynch RM, Alam SM, Moody MA, Ferrari G, Berrong M, Kelsoe G, Shaw GM, Hahn BH, Montefiori DC, Kamanga G, Cohen MS, Hraber P, Kwong PD, Korber BT, Mascola JR, Kepler TB, Haynes BF. Cell. 2014 Jul 23. pii: S0092-8674(14)00812-5. doi: 10.1016/j.cell.2014.06.022.

  34. HIV-1 Specific IgA Detected in Vaginal Secretions of HIV Uninfected Women Participating in a Microbicide Trial in Southern Africa Are Primarily Directed Toward gp120 and gp140 Specificities.
    Seaton KE, Ballweber L, Lan A, Donathan M, Hughes S, Vojtech L, Moody MA, Liao HX, Haynes BF, Galloway CG, Richardson BA, Karim SA, Dezzutti CS, McElrath MJ, Tomaras GD, Hladik F. PLoS One. 2014 Jul 23; 9(7): e101863. doi: 10.1371/journal.pone.0101863. eCollection 2014.

  35. Reversion and T Cell Escape Mutations Compensate the Fitness Loss of a CD8+ T Cell Escape Mutant in Their Cognate Transmitted/Founder Virus.
    Song H, Hora B, Bhattacharya T, Goonetilleke N, Liu MK, Wiehe K, Li H, Iyer SS, McMichael AJ, Perelson AS, Gao F. PLoS One. 2014 Jul 16;9(7):e102734. doi: 10.1371/journal.pone.0102734. eCollection 2014.

  36. HIV-1 Antibodies and Vaccine Antigen Selectively Interact with Lipid Domains.
    Hardy GJ, Wong GC, Nayak R, Anasti K, Hirtz M, Shapter JG, Alam SM, Zauscher S. Biochim Biophys Acta. 2014 Jul 11. pii: S0005-2736(14)00251-X. doi: 10.1016/j.bbamem.2014.07.007.

  37. Will studies in individuals with systemic lupus erythematosus be the key to future HIV vaccine design?
    Bonsignori M. Expert Rev Vaccines. 2014 Jul 12:1-4.

  38. Envelope Glycoprotein Binding to the α4β7 Integrin Complex is not a General Property of Most HIV-1 Variants.
    Perez LG, Chen H, Liao HX, Montefiori DC. J Virol. 2014 Jul 9. pii: JVI.03296-13.

  39. Histone Deacetylation Critically Determines T Cell Subset Radiosensitivity.
    Pugh JL, Sukhina AS, Seed TM, Manley NR, Sempowski GD, van den Brink MR, Smithey MJ, Nikolich-Žugich J. J Immunol. 2014 Jul 2. pii: 1400434.

  40. Toward development of a comprehensive external quality assurance program for polyfunctional intracellular cytokine staining assays.
    Staats JS, Enzor JH, Sanchez AM, Rountree W, Chan C, Jaimes M, Chan RC, Gaur A, Denny TN, Weinhold KJ. J Immunol Methods. 2014 Jun 23. pii: S0022-1759(14)00186-0. doi: 10.1016/j.jim.2014.05.021. Review.

  41. Affinity maturation in an HIV broadly neutralizing B-cell lineage through reorientation of variable domains.
    Fera D, Schmidt AG, Haynes BF, Gao F, Liao HX, Kepler TB, Harrison SC. Proc Natl Acad Sci U S A. 2014 Jun 30. pii: 201409954.

  42. Human Responses to Influenza Vaccination Show Seroconversion Signatures and Convergent Antibody Rearrangements.
    Jackson KJ, Liu Y, Roskin KM, Glanville J, Hoh RA, Seo K, Marshall EL, Gurley TC, Moody MA,  Haynes BF, Walter EB, Liao HX, Albrecht RA, García-Sastre A, Chaparro-Riggers J, Rajpal A, Pons J, Simen BB, Hanczaruk B, Dekker CL, Laserson J, Koller D, Davis MM, Fire AZ, Boyd SD. Cell Host Microbe. 2014 Jun 25. pii: S1931-3128(14)00184-X. doi: 10.1016/j.chom.2014.05.013.

  43. Leukopak PBMC sample processing for preparing quality control material to support proficiency testing programs.
    Garcia A, Keinonen S, Sanchez AM, Ferrari G, Denny TN, Moody MA. J Immunol Methods. 2014 Jun 10. pii: S0022-1759(14)00181-1.

  44. The Variable Loop 3 in the Envelope Glycoprotein Is Critical for the Atypical Coreceptor Usage of an HIV-1 Strain.
    Xiang Y, Liu W, Chen Y, Zhang C, Su W, Zhang Y, Sun J, Gao F, Jiang C. PLoS One. 2014 Jun 4;9(6):e98058.

  45. The Human Antibody Response to the Surface of Mycobacterium tuberculosis.
    Perley CC, Frahm M, Click EM, Dobos KM, Ferrari G, Stout JE, Frothingham R. PLoS One. 2014 Jun 11;9(2):e98938. doi: 10.1371/journal.pone.0098938. eCollection 2014.

  46. Vaccine induced HIV-1 envelope gp120 Constant Region 1-specific Antibodies Expose a CD4-inducible Epitope and Block the Interaction of HIV-1 gp140 With Galactosylceramide.
    Dennison SM, Anasti KM, Jaeger FH, Stewart SM, Pollara J, Liu P, Kunz EL, Zhang R, Vandergrift N, Permar S, Ferrari G, Tomaras GD, Bonsignori M, Michael NL, Kim JH, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Liao HX, Haynes BF, Alam SM. J Virol. 2014 Jun 11. pii: JVI.01031-14.

  47. The Immunology Quality Assessment Proficiency Testing Program for CD3+4+ and CD3+8+Lymphocyte Subsets: A ten year review via longitudinal mixed effects modeling.
    Bainbridge J, Wilkening CL, Rountree W, Louzao R, Wong J, Perza N, Garcia A, Denny TN. J Immunol Methods. 2014 Jun 6. pii: S0022-1759(14)00179-3. doi: 10.1016/j.jim.2014.05.017. Review.

  48. The Center for HIV/AIDS Vaccine Immunology (CHAVI) Multi-site Quality Assurance Program for Cryopreserved Human Peripheral Blood Mononuclear Cells.
    Sarzotti-Kelsoe M, Needham LK, Rountree W, Bainbridge J, Gray CM, Fiscus SA, Ferrari G, Stevens WS, Stager SL, Binz W, Louzao R, Long KO, Mokgotho P, Moodley N, Mackay M, Kerkau M, McMillion T, Kirchherr J, Soderberg KA, Haynes BF, Denny TN. J Immunol Methods. 2014 Jun 5. pii: S0022-1759(14)00175-6. doi: 10.1016/j.jim.2014.05.013.

  49. Redemption of autoreactive B cells.
    Haynes BF, Verkoczy L, Kelsoe G. Proc Natl Acad Sci U S A. 2014 Jun 11. pii: 201407877.  No abstract available.

  50. Introduction for JIM Special Issue: Building Global Resource Programs to Support HIV/AIDS Clinical Trial Studies.
    Sanchez AM, Denny TN, O'Gorman M. J Immunol Methods. 2014 Jun 5. pii: S0022-1759(14)00178-1. doi: 10.1016/j.jim.2014.05.016. No abstract available.

  51. Transcriptional and Post-transcriptional Regulation of Cytokine Gene Expression in HIV-1 Antigen-specific CD8+ T Cells that Mediate Virus Inhibition.
    Payne TL, Blackinton J, Frisbee A, Pickeral J, Sawant S, Vandergrift NA, Freel SA, Ferrari G, Keene JD, Tomaras GD. J Virol. 2014 Jun 4. pii: JVI.00802-14.

  52. Which comes first: the antigen or the adjuvant?
    Permar SR, Staats HF. J Clin Invest. 2014 Jun 2;124(6):2364-5. doi: 10.1172/JCI76263. Epub 2014 May 16.

  53. Dusp3 and Psme3 Are Associated with Murine Susceptibility to Staphylococcus aureus Infection and Human Sepsis.
    Yan Q, Sharma-Kuinkel BK, Deshmukh H, Tsalik EL, Cyr DD, Lucas J, Woods CW, Scott WK,Sempowski GD, Thaden J, Rude TH, Ahn SH, Fowler VG Jr. PLoS Pathog. 2014 Jun 5;10(6):e1004149. doi: 10.1371/journal.ppat.1004149. eCollection 2014 Jun.

  54. The Haemophilus ducreyi trimeric autotransporter adhesin DsrA protects against an experimental infection in the swine model of chancroid.
    Fusco WG, Choudhary NR, Routh PA, Ventevogel MS, Smith VA, Koch GG, Almond GW, Orndorff PE, Sempowski GD, Leduc I. Vaccine. 2014 May 17. pii: S0264-410X(14)00698-7. doi: 10.1016/j.vaccine.2014.05.031.

  55. IFN-γ, but not IL-17A, is required for survival during secondary pulmonary Francisella tularensis Live Vaccine Stain infection.
    Roberts LM, Davies JS, Sempowski GD, Frelinger JA. Vaccine. 2014 May 14. pii: S0264-410X(14)00669-0. doi: 10.1016/j.vaccine.2014.05.013.

  56. Cross-reactive potential of human T-lymphocyte responses in HIV-1 infection.
    Giorgi EE, Balachandran H, Muldoon M, Letvin NL, Haynes BF, Korber BT, Santra S. Vaccine. 2014 May 13. pii: S0264-410X(14)00578-7. doi: 10.1016/j.vaccine.2014.04.040.

  57. HIV-1 envelope gp41 broadly neutralizing antibodies: hurdles for vaccine development.
    Verkoczy L, Kelsoe G, Haynes BF. PLoS Pathog. 2014 May 22;10(5):e1004073. doi: 10.1371/journal.ppat.1004073. eCollection 2014 May. No abstract available.

  58. AIDS/HIV. Host controls of HIV neutralizing antibodies.
    Haynes BF, Verkoczy L. Science. 2014 May 9;344(6184):588-9. doi: 10.1126/science.1254990. Summary l Reprint l Full Text

  59. HIV-1 vaccine-induced C1 and V2 Env-specific antibodies synergize for increased antiviral activities.
    Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, Hwang KK, Gurley TC, Kozink DM, Armand LC, Marshall DJ, Whitesides JF, Kaewkungwal J, Nitayaphan S, Pitisuttithum P, Rerks-Ngarm S, Robb ML, O'Connell RJ, Kim JH, Michael NL, Montefiori DC, Tomaras GD, Liao HX, Haynes BF, Ferrari G. J Virol. 2014 May 7.

  60. Development and implementation of a proficiency testing program for Luminex bead-based cytokine assays.
    Lynch HE, Sanchez AM, D'Souza MP, Rountree W, Denny TN, Kalos M, Sempowski GD. J Immunol Methods. 2014 May 4. pii: S0022-1759(14)00128-8. doi: 10.1016/j.jim.2014.04.011. Review.

  61. Analysis of HLAA*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.
    Gartland AJ, Li S, McNevin J, Tomaras GD, Gottardo R, Janes H, Fong Y, Morris D, Geraghty DE, Kijak GH, Edlefsen PT, Frahm N, Larsen BB, Tovanabutra S, Sanders-Buell E, deCamp AC, Magaret CA, Ahmed H, Goodridge JP, Chen L, Konopa P, Nariya S, Stoddard JN, Wong K, Zhao H, Deng W, Maust BS, Bose M, Howell S, Bates A, Lazzaro M, O'Sullivan A, Lei E, Bradfield A, Ibitamuno G, Assawadarachai V, O'Connell RJ, deSouza MS, Nitayaphan S, Rerks-Ngarm S, Robb ML, Sidney J, Sette A, Zolla-Pazner S, Montefiori D, McElrath MJ, Mullins JI, Kim JH, Gilbert PB, Hertz T. J Virol. 2014 May 14. pii: JVI.01164-14.

  62. Reconstructing a B-Cell Clonal Lineage. II. Mutation, Selection, and Affinity Maturation.
    Kepler TB, Munshaw S, Wiehe K, Zhang R, Yu JS, Woods CW, Denny TN, Tomaras GD, Alam SM, Moody MA, Kelsoe G, Liao HX, Haynes BF. Front Immunol. 2014 Apr 22;5:170. doi: 10.3389/fimmu.2014.00170. eCollection 2014.

  63. Osuna CE, Gonzalez AM, Chang HH, Hung AS, Ehlinger E, Anasti K, Alam SM, Letvin NL. TCR Affinity Associated with Functional Differences between Dominant and Subdominant SIV Epitope-Specific CD8+ T Cells in Mamu-A*01+ Rhesus Monkeys. PLoS Pathog. 2014 Apr 17;10(4):e1004069. doi: 10.1371/journal.ppat.1004069. eCollection 2014 Apr.

  64. Nair SK, Tomaras GD, Sales AP, Boczkowski D, Chan C, Plonk K, Cai Y, Dannull J, Kepler TB, Pruitt SK, Weinhold KJ. High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes. Sci Rep. 2014 Apr 23;4:4632.

  65. Verkoczy L, Diaz M. Autoreactivity in HIV-1 broadly neutralizing antibodies: implications for their function and induction by vaccination. Curr Opin HIV AIDS. 2014 May; 9(3): 224-34.

  66. Tomaras GD, Montefiori DC. Spectrum of HIV antibodies in vaccine and disease. Curr Opin HIV AIDS. 2014 May;9(3):207-9.

  67. Moody MA. Modulation of HIV-1 immunity by adjuvants. Curr Opin HIV AIDS. 2014 May; 9(3): 242-9.

  68. Madani N, Princiotto AM, Schön A, Lalonde J, Feng Y, Freire E, Park J, Courter JR, Jones DM, Robinson J, Liao HX, Moody MA, Permar S, Haynes B, Smith AB 3rd, Wyatt R, Sodroski J. CD4-mimetic Small Molecules Sensitize Human Immunodeficiency Virus (HIV-1) to Vaccine-elicited Antibodies. J Virol. 2014 Apr 2. [Epub ahead of print]

  69. Richards AJ, Staats J, Enzor J, McKinnon K, Frelinger J, Denny TN, Weinhold KJ, Chan C.Setting objective thresholds for rare event detection in flow cytometry. J Immunol Methods. 2014 Apr 10. pii: S0022-1759(14)00118-5. [Epub ahead of print] Review.

  70. Smith KL, Saini D, Bardarov S, Larsen M, Frothingham R, Gandhi NR, Jacobs WR Jr, Sturm AW, Lee S. Reduced Virulence of an Extensively Drug-Resistant Outbreak Strain of Mycobacterium tuberculosis in a Murine Model. PLoS One. 2014 Apr 14;9(4): e94953.

  71. Establishment and maintenance of a PBMC repository for functional cellular studies in support of clinical vaccine trials.
    Sambor A, Garcia A, Berrong M, Pickeral J, Brown S, Rountree W, Sanchez A, Pollara J, Frahm N, Keinonen S, Kijak GH, Roederer M, Levine G, D'Souza MP, Jaimes M, Koup R, Denny T, Cox J, Ferrari G. J Immunol Methods. 2014 Apr 29. pii: S0022-1759(14)00122-7. doi: 10.1016/j.jim.2014.04.005. [Epub ahead of print] Review.

  72. Meyer SA, Westreich DJ, Patel E, Ehlinger EP, Kalilani L, Lovingood RV, Denny TN, Swamy GK, Permar SR. Postnatal Cytomegalovirus Exposure in Infants of Antiretroviral-Treated and Untreated HIV-Infected Mothers. Infect Dis Obstet Gynecol. 2014: 989721.

  73. Packiam M, Yedery R, Begum AA, Carlson RW, Ganguly J, Sempowski GD, Ventevogel MS, Shafer WM, Jerse AE. Phosphoethanolamine Decoration of Neisseria gonorrhoeae Lipid A Plays a Dual Immunostimulatory and Protective Role during Experimental Genital Tract Infection. Infect Immun. 2014 Mar 31. [Epub ahead of print]

  74. Chahroudi A, Cartwright E, Lee ST, Mavigner M, Carnathan DG, Lawson B, Carnathan PM, Hashempoor T, Murphy MK, Meeker T, Ehnert S, Souder C, Else JG, Cohen J, Collman RG, Vanderford TH, Permar SR, Derdeyn CA, Villinger F, Silvestri G. Target cell availability, rather than breast milk factors, dictates mother-to-infant transmission of SIV in sooty mangabeys and rhesus macaques. PLoS Pathog. 2014 Mar 6;10(3): e1003958.

  75. The External Quality Assurance Oversight Laboratory (EQAPOL) proficiency program forIFN-gamma enzyme-linked immunospot (IFN-γ ELISpot) assay.
    Sanchez AM, Rountree W, Berrong M, Garcia A, Schuetz A, Cox J, Frahm N, Manak M, Sarzotti-Kelsoe M, D'Souza MP, Denny T, Ferrari G. J Immunol Methods. 2014 Mar 28. pii: S0022-1759(14)00091-X. doi: 10.1016/j.jim.2014.03.017. [Epub ahead of print] Review.

  76. Jalah R, Kulkarni V, Patel V, Rosati M, Alicea C, Bear J, Yu L, Guan Y, Shen X, Tomaras GD, Labranche C, Montefiori DC, Prattipati R, Pinter A, Bess J Jr, Lifson JD, Reed SG, Sardesai NY, Venzon DJ, Valentin A, Pavlakis GN, Felber BK. DNA and protein co-immunization improves the magnitude and longevity of humoral immune responses in macaques. PLoS One. 2014 Mar 13; 9(3): e91550.

  77. Roberts LM, Tuladhar S, Steele SP, Riebe KJ, Chen CJ, Cumming RI, Seay S, Frothingham R, Sempowski GD, Kawula TH, Frelinger JA. Identification of Early Interactions Between Francisella and the Host. Infect Immun. 2014 Mar 31. [Epub ahead of print]

  78. Sarzotti-Kelsoe M, Daniell X, Todd CA, Bilska M, Martelli A, Labranche C, Perez LG, Ochsenbauer C, Kappes JC, Rountree W, Denny TN, Montefiori DC. Optimization and validation of a neutralizing antibody assay for HIV-1 in A3R5 cells. J Immunol Methods. 2014 Mar 6. pii: S0022-1759(14)00072-6.

  79. Yates NL, Liao HX, Fong Y, Decamp A, Vandergrift NA, Williams WT, Alam SM, Ferrari G, Yang ZY, Seaton KE, Berman PW, Alpert MD, Evans DT, O'Connell RJ, Francis D, Sinangil F, Lee C, Nitayaphan S, Rerks-Ngarm S, Kaewkungwal J, Pitisuttithum P, Tartaglia J, Pinter A, Zolla-Pazner S, Gilbert PB, Nabel GJ, Michael NL, Kim JH, Montefiori DC, Haynes BF, Tomaras GD. Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. Sci Transl Med. 2014 Mar 19;6(228): 228ra39.

  80. Hwang KK, Trama AM, Kozink DM, Chen X, Wiehe K, Cooper AJ, Xia SM, Wang M, Marshall DJ, Whitesides J, Alam M, Tomaras GD, Allen SL, Rai KR, McKeating J, Catera R, Yan XJ, Chu CC, Kelsoe G, Liao HX, Chiorazzi N, Haynes BF. IGHV1-69 B Cell Chronic Lymphocytic Leukemia Antibodies Cross-React with HIV-1 and Hepatitis C Virus Antigens as Well as Intestinal Commensal Bacteria. PLoS One. 2014 Mar 10; 9(3): e90725.

  81. Bonsignori M, Wiehe K, Grimm SK, Lynch R, Yang G, Kozink DM, Perrin F, Cooper AJ, Hwang KK, Chen X, Liu M, McKee K, Parks RJ, Eudailey J, Wang M, Clowse M, Criscione-Schreiber LG, Moody MA, Ackerman ME, Boyd SD, Gao F, Kelsoe G, Verkoczy L, Tomaras GD, Liao HX, Kepler TB, Montefiori DC, Mascola JR, Haynes BF. An autoreactive antibody from an SLE/HIV-1 individual broadly neutralizes HIV-1. J Clin Invest. 2014.

  82. Holl TM, Yang G, Kuraoka M, Verkoczy L, Alam SM, Moody MA, Haynes BF, Kelsoe G. Enhanced Antibody Responses to an HIV-1 Membrane-Proximal External Region Antigen in Mice Reconstituted with Cultured Lymphocytes. J Immunol. 2014 Mar 3. [Epub ahead of print]

  83. Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates.
    Tomaras GD, Haynes BF. Vaccines (Basel). 2014 Mar; 2(1): 15-35.

  84. Zullo AJ, Jurcic Smith KL, Lee S. Mammalian target of Rapamycin inhibition and mycobacterial survival are uncoupled in murine macrophages. BMC Biochem. 2014 Feb 14;15(1):4. doi: 10.1186/1471-2091-15-4.

  85. Lynch HE, Stewart SM, Kepler TB, Sempowski GD, Alam SM. Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen. J Immunol Methods. 2014 Feb; 404:1-12.

  86. Hu B, Liao HX, Alam SM, Goldstein B. Estimating the probability of polyreactive antibodies 4E10 and 2F5 disabling a gp41 trimer after T cell-HIV adhesion. PLoS Comput Biol. 2014 Jan 30;10(1):e1003431. doi: 10.1371/journal.pcbi.1003431. eCollection 2014 Jan.

  87. Rountree W, Vandergrift N, Bainbridge J, Sanchez AM, Denny TN. Statistical methods for the assessment of EQAPOL proficiency testing: ELISpot, Luminex, and Flow Cytometry. J Immunol Methods. 2014 Jan 20. pii: S0022-1759(14)00017-9. doi: 10.1016/j.jim.2014.01.007. [Epub ahead of print] Review.

  88. Zolla-Pazner S, Decamp A, Gilbert PB, Williams C, Yates NL, Williams WT, Howington R, Fong Y, Morris DE, Soderberg KA, Irene C, Reichman C, Pinter A, Parks R, Pitisuttithum P, Kaewkungwal J, Rerks-Ngarm S, Nitayaphan S, Andrews C, O'Connell RJ, Yang ZY, Nabel GJ, Kim JH, Michael NL, Montefiori DC, Liao HX, Haynes BF, Tomaras GD. PLoS One. 2014 Feb 4;9(2):e87572. doi: 10.1371/journal.pone.0087572. eCollection 2014.

  89. Reardon PN, Sage H, Dennison SM, Martin JW, Donald BR, Alam SM, Haynes BF, Spicer LD. Structure of an HIV-1-neutralizing antibody target, the lipid-bound gp41 envelope membrane proximal region trimer. Proc Natl Acad Sci U S A. 2014 Jan 28;111(4):1391-6. doi: 10.1073/pnas.1309842111. Epub 2014 Jan 13.

  90. Zhang J, Alam SM, Bouton-Verville H, Chen Y, Newman A, Stewart S, Jaeger FH, Montefiori DC, Dennison SM, Haynes BF, Verkoczy L. Modulation of Nonneutralizing HIV-1 gp41 Responses by an MHC-Restricted TH Epitope Overlapping Those of Membrane Proximal External Region Broadly Neutralizing Antibodies. J Immunol. 2014 Jan 24. [Epub ahead of print]

  91. Goepfert PA, Elizaga ML, Seaton KE, Tomaras GD, Montefiori DC, Sato A, Hural J, Derosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder S, Hammer S, Koblin B, Pensiero M, Butler C, Moss B, Robinson HL; the HVTN 205 Study Group; the National Institutes of Allergy and Infectious Diseases HIV Vaccines Trials Network. Specificity and Six-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles. J Infect Dis. 2014 Jan 7. [Epub ahead of print]

  92. Holmer SM, Evans KS, Asfaw YG, Saini D, Schell WA, Ledford JG, Frothingham R, Wright JR, Sempowski GD, Perfect JR, Pirofski L. Impact of surfactant protein d, interleukin-5, and eosinophilia on cryptococcosis. Infect Immun. 2014 Feb; 82(2): 683-93. doi: 10.1128/IAI.00855-13.

  93. Sanchez AM, Demarco CT, Hora B, Keinonen S, Chen Y, Brinkley C, Stone M, Tobler L, Keating S, Schito M, Busch MP, Gao F, Denny TN. Development of a Contemporary Globally Diverse HIV Viral Panel by the EQAPOL Program. J Immunol Methods. 2014 Jan 18. pii: S0022-1759(14)00014-3. [Epub ahead of print]

  94. Moody MA, Santra S, Vandergrift NA, Sutherland LL, Gurley TC, Drinker MS, Allen AA, Xia SM, Meyerhoff RR, Parks R, Lloyd KE, Easterhoff D, Alam SM, Liao HX, Ward BM, Ferrari G, Montefiori DC, Tomaras GD, Seder RA, Letvin NL, Haynes BF. TLR-7/8 and 9 Agonists Cooperate to Enhance HIV-1 Envelope Antibody Responses in Rhesus Macaques. J Virol. 2014 Jan 3. [Epub ahead of print]

  95. Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.
    Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, Ward BM, Bailer RT, Gottardo R, Gu W, Ferrari G, Alam SM, Denny TN, Montefiori DC, Tomaras GD, Korber BT, Nason MC, Seder RA, Koup RA, Letvin NL, Rao SS, Nabel GJ, Mascola JR. Nature. 2014 Jan 23;505(7484):502-8. doi: 10.1038/nature12893. Epub 2013 Dec 18.